Fusion proteins of anaplastic lymphoma kinase (ALK) are emerging therapeutic targets for cancer and other human diseases, especially non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma(ALCL).121,122 So far, five ALK inhibitors, including Alectinib, Brigatinib, Ceritinib, Crizotinib, and Lorlatinib have been approved by the FDA for the treatment of ALK-positive NSCLC. This evidence concerns the gene ALK and non-small cell lung carcinoma.